Deuteration is the replacement of a hydrogen atom by deuterium atom in a molecule. The replacement begins at the most acidic hydrogen in the molecule. In ATP, the deshielded hydrogen is C8-H which is the first replaced during deuteration. During ATP deuteration some of the ATP is hydrolysed to ADP concurrently. Using kinetic analysis, it was confirmed that the ATP hydrolysis that occurs is 1st order in ATP concentration, while the hydrogen replacement is 2nd order. The ATP and its C8 deuterated analogue were tested against three enzymes shikimate kinase (SK), acetate kinase (AK) and glutamine synthetase (GS) to determine if a kinetic isotope effect (KIE) exists in these systems. With AK and GS, the KIED increased as the KIEH decreased, while with SK the KIED decreased as the KIEH increased as the concentration of the ATP or deuterated analogue increased. Deuteration of imidazole and purine compounds reduced the specific activity of AK or SK at low concentrations in an enzyme-catalysed reaction. From a library of imidazole-containing compounds that inhibited SK, three compounds were selected and their IC50 values were determined on the SK-catalysed reaction. These compounds show a differential potency and efficiency between their protonated and deuterated analogues when compared in a 1:1 mixture. Synthesized purines incorporating three different substituents at N-9 were tested against AK or SK for their ability to lower the specific activity of the enzymes used / Physics / M. Sc. (Physics)

Background: Pulmonary hypertension (PH) is a rare condition characterized by endothelial dysfunction and vascular remodelling, leading to increased pulmonary vascular resistance (PVR) and right ventricular heart failure. Endothelial dysfunction is associated with an imbalance between vasoconstrictor compounds, such as endothelin and thromboxane A2, and vasodilator compounds, such as prostacyclin and nitric oxide (NO). Asymmetric dimethylarginine (ADMA), a methyl derivate of L-arginine, inhibits synthesis of NO. Vardenafil, a phosphodiesterase type 5 inhibitor (PDE5-inhibitors), causes vasodilation through the NO/cGMP pathway. Aim: This thesis investigates the pharmacological effects and diagnostic utility of vardenafil in PH patients. In addition, to evaluate the change of L-arginine and dimethylarginines before and during PAHspecific therapy in PAH patients compared to patients with left ventricular heart failure (LVHF) and healthy subjects. Methods: The pharmacokinetics and hemodynamic effects of vardenafil were examined during right heart catheterization (RHC) in 16 PH patients and plasma concentrations were measured for up to nine hours after oral administration. In 20 PH patients, acute vasoreactivity test with vardenafil was performed during RHC. Hemodynamic responses were recorded, responders were defined and followed for up to seven years. Additionally, plasma ADMA, symmetric dimethylarginine (SDMA), L-arginine, L-citrulline and L-ornithine levels before and after PAH drug treatment were monitored in 21 PAH patients and compared to values measured in 14 LVHF patients and 27 healthy subjects. Results: Vardenafil concentrations increased rapidly to maximum plasma concentration (tmax 1h) and elimination half-life was 3.4 h. Patients co-medicated with bosentan had reduced vardenafil concentration. Significant acute hemodynamic responses were observed for mean pulmonary artery pressure (mPAP) (p<0.001), pulmonary vascular resistance (PVR) (p<0.001), cardiac output (CO) (p=0.015), cardiac index (CI) (p=0.010), systemic vascular resistance (SVR) (p<0.001) and PVR/SVR (p=0.002) and were related to plasma vardenafil concentrations. PAH patients had significantly higher ADMA and SDMA levels and significantly lower L-arginine levels and L-arginine/ADMA ratio compared with healthy subjects (p<0.001). L-arginine was also lower in PAH patients compared to patients with LVHF (p<0.05). WHO functional class and six minutes walking distance (6MWD) correlated to Larginine and L-arginine/ADMA ratio in PAH at baseline (p<0.05). At follow-up, patients on mono- or combinationtherapy with endothelin receptor antagonists (ERA) had lower ADMA levels than patients without ERA (p<0.05). In contrast, patients on PDE5-inhibitors had higher ADMA levels compared to patients without PDE5-inhibitors (p<0.05). Conclusion: Vardenafil is safe in acute vasoreactivity test in PH patients. Cardiopulmonary hemodynamic response was related to plasma drug concentrations. There was a high inter-individual variability of vardenafil pharmacokinetics and co-medication with bosentan caused a pharmacokinetic drug interaction. Baseline L-arginine and dimethylarginines levels were different in PAH patients compared to LVHF patients and healthy controls. PAH-specific treatment influenced L-arginine and dimethylarginines. Our data suggest that L-arginine might be useful for differentiating PAH from LVHF, and L-arginine/ADMA ratios were related to the severity of PAH and might be useful for follow-up evaluations of PAH patients.

Les nucléotides et nucléosides sont des molécules essentielles à la vie. Outre leurs fonctions intracellulaires, ils jouent un rôle dans la communication intercellulaire. Les nucléotides et nucléosides sont libérés dans l’espace extracellulaire par différents mécanismes et ensuite rapidement métabolisés par des ecto-nucléotidases. Ils exercent leurs effets paracrines et/ou autocrines en activant des récepteurs présents à la surface membranaire des cellules. Les récepteurs P1, au nombre de quatre (A1, A2A, A2B et A3), sont activés par l’adénosine. Les récepteurs P2X1-7 ont une activité intrinsèque de canal ionique et sont essentiellement activés par l’ATP. Les récepteurs P2Y possèdent sept domaines transmembranaires et sont couplés à des protéines G. A ce jour huit sous-types ont été identifiés : P2Y1,2,4,6,11,12,13,14. Ces récepteurs sont activés par des nucléotides adényliques (ATP et ADP) et/ou uridyliques (UTP, UDP et UDP-glucose). Les récepteurs P1 et P2 modulent l’activité de multiples processus biologiques : système immunitaire (A2A, P2X7, P2Y11,…), agrégation plaquettaire (P2Y1, P2Y12, P2X1), tonus vasculaire, angiogenèse,… Notre laboratoire a identifié et caractérisé plusieurs récepteurs P2Y : P2Y4, P2Y6, P2Y11 et P2Y13. Ce dernier est activé par l’ADP et est couplé à une protéine Gi. L’abondance du transcrit P2Y13 murin est caractérisée par l’ordre suivant : rate >> pancréas > foie = cerveau. Afin de déterminer son rôle physiologique, nous avons généré une lignée de souris invalidées pour le récepteur P2Y13. Après avoir validé l’inactivation du gène P2Y13 dans ces souris, nous avons analysé leur phénotype. Les souris P2Y13-/- ne présentent pas d’anomalie évidente : elles sont viables, fertiles et se développent normalement. Etant donné le profil d’expression de ce récepteur, nous avons analysé leur système immunitaire, en particulier les cellules dendritiques (DC). In vivo, l’invalidation du récepteur P2Y13 ne semble pas avoir d’impact sur les réponses inflammatoires (choc septique, infiltration de neutrophiles, test à la formaline) et auto-immunes (uvéorétinite expérimentale). In vitro, nous avons montré que l’ADPβS induit une mobilisation de calcium cytoplasmique dans les DC spléniques et qu’il stimule l’endocytose d’antigènes par celles-ci. L’utilisation de DC transgéniques a permis d’exclure l’implication du récepteur P2Y13 et a montré que ces effets sont médiés par le récepteur P2Y12 qui est également activé par l’ADPβS. Ces observations suggèrent qu’il serait intéressant d’analyser le système immunitaire des souris P2Y12-/-, en particulier les réponses immunes dépendantes des DC. D’autre part, ce travail a débouché sur la mise en évidence d’un effet anti-inflammatoire médié par le récepteur de l’adénosine A2B dans les DC dérivées de la moelle osseuse. Enfin, nous avons récemment mis en évidence un rôle potentiel du récepteur P2Y13 dans le métabolisme des glucides et des lipides. Nous avons observé que les souris P2Y13-/- produisent plus d’insuline en réponse à une injection de glucose que les souris contrôles tandis que leur glycémie ne semble pas altérée. De plus, les souris P2Y13-/- sous régime riche en graisses reproduisent 3 caractéristiques du syndrome métabolique chez l'homme : surpoids, dyslipidémie (augmentation des triglycérides et du non HDL-cholestérol) et hyperinsulinémie. Notre travail de thèse débouche donc sur deux conclusions et une perspective : • l’adénosine exerce une action anti-inflammatoire sur les cellules dendritiques dérivées de moelle osseuse via l’activation du récepteur A2B ; • le récepteur P2Y12 est exprimé fonctionnellement dans les cellules dendritiques murines et stimule l’endocytose ; • le récepteur P2Y13 pourrait jouer un rôle important dans le contrôle du métabolisme des lipides et des glucides ainsi que du poids corporel, suggérant que des agonistes spécifiques de ce récepteur pourraient permettre de contrecarrer l’obésité et ses conséquences métaboliques néfastes.

Ribonucleotide reductase (RNR) is a key enzyme for de novo dNTP biosynthesis. We have studied nucleotide-dependent oligomerization of the allosterically regulated mammalian RNR using a mass spectrometry–related technique called Gas-phase Electrophoretic Mobility Macromolecule Analysis (GEMMA). Our results showed that dATP and ATP induce the formation of an α6β2 protein complex. This complex can either be active or inactive depending on whether ATP or dATP is bound. In order to understand whether formation of the large complexes is a general feature in the class Ia RNRs, we compared the mammalian RNR to the E. coli enzyme. The E. coli protein is regarded a prototype for all class Ia RNRs. We found that the E. coli RNR cycles between an active α2β2 form (in the presence of ATP, dTTP or dGTP) and an inactive α4β4 form in the presence of dATP or a combination of ATP with dTTP/dGTP. The E. coli R1 mutant (H59A) which needs higher dATP concentrations to be inhibited than the wild-type enzyme had decreased ability to form these complexes. It remains to be discovered how the regulation functions in the mammalian enzyme where both the active and inactive forms are α6β2 complexes. An alternative way to produce dNTPs is via salvage biosynthesis where deoxyribonucleosides are taken up from outside the cell and phosphorylated by deoxyribonucleoside kinases. We have found that the pathogen Trypanosoma brucei, which causes African sleeping sickness, has a very efficient salvage of adenosine, deoxyadenosine and adenosine analogs such as adenine arabinoside (Ara-A). One of the conclusions made was that this nucleoside analog is phosphorylated by the T. brucei adenosine kinase and kills the parasite by causing nucleotide pool imbalances and by incorporation into nucleic acids. Ara-A-based therapies can hopefully be developed into new medicines against African sleeping sickness. Generally, the dNTPs produced from the de novo and salvage pathways can be imported into mitochondria and participate in mtDNA replication. The minimal mtDNA replisome contains DNA polymerase γA, DNA polymerase γB, helicase (TWINKLE) and the mitochondrial single-stranded DNA-binding protein (mtSSB). Here, it was demonstrated that the primase-related domain (N-terminal region) of the TWINKLE protein lacked primase activity and instead contributes to single-stranded DNA binding and DNA helicase activities. This region is not absolutely required for mitochondrial DNA replisome function but is needed for the formation of long DNA products.

La grande disponibilité et les propriétés psychostimulantes de la caféine en font l’un des psychostimulants les plus consommés mondialement. Sa capacité à augmenter la vigilance serait reliée à son action antagoniste des récepteurs adénosinergiques. Le vieillissement s'accompagne de changements dans les mécanismes de régulation de la vigilance, y compris le système adénosinergique, qui pourraient moduler les effets de la caféine. Alors que plusieurs études ont investigué les impacts de la caféine sur la vigilance chez une population jeune, peu ont identifié les effets chez une population plus âgée. Deux protocoles expérimentaux pouvant distinguer les effets différentiels de la caféine selon l’âge ont été élaborés. La première étude a évalué les effets de 200 mg de caféine sur la vigilance, comparée à un placebo, chez une population jeune et d’âge moyen lors d’une privation de sommeil de 25 heures. L’augmentation de la vigilance subjective et de la performance psychomotrice suite à l’administration de caféine est comparable dans les deux groupes d’âge. Or, des modifications de la puissance spectrale de certaines bandes de fréquences de l’EEG d’éveil suite à l’administration de la caféine sont spécifiques au groupe d’âge moyen. Une deuxième étude a évalué les effets de 200 mg de caféine sur la vigilance, comparée à un placebo, chez des sujets jeunes et d’âge moyen consommateurs légers de caféine. La caféine n’a pas augmenté la vigilance subjective des consommateurs légers. Par ailleurs, la caféine a augmenté la performance psychomotrice de façon similaire dans les deux groupes d’âge. De plus, on remarque que la caféine induit des modifications de la puissance spectrale sur certaines bandes de fréquences à l’EEG chez le groupe d’âge moyen uniquement. Ces travaux suggèrent tout d’abord que la caféine tend à augmenter la vigilance, peu importe le niveau basal d’alerte. De plus, malgré l’absence d’effet subjectif de la caféine sur la vigilance, les consommateurs légers de caféine montrent des effets sur les mesures objectives de la vigilance. Bien que la caféine augmente la vigilance chez les deux groupes d’âge, la spécificité de certaines modifications relevées à l’EEG suggère une augmentation de la sensibilité à la caféine selon l’âge. Il est possible qu’il existe des changements du système adénosinergique au cours du vieillissement qui sous-tendent les effets différentiels de la caféine au cours du vieillissement. / The availability and psychoactive properties of caffeine make it one of the most widely consumed behaviourally active substances in the world. The capacity of caffeine to increase vigilance relies on its antagonist action on adenosine receptors. Aging is associated with changes in the mechanisms regulating vigilance, possibly through changes in the adenosinergic system which could in turn affect eh influence of caffeine. While extensive research identified the impacts of caffeine on vigilance in young populations, few studies have investigated the effects in an older population. Two experimental protocols which can highlight the differential effects of caffeine according to age were elaborated. The first study estimated the effects of 200 mg of caffeine on vigilance, compared with a placebo, in young and middle-aged subjects during 25 hours of sleep deprivation. Caffeine increased subjective and psychomotor measures similarly in young and middle-aged subjects. However, modifications of the spectral power in some frequencies bands after caffeine ingestion were specific to the middle-aged group. The second study focused on the effects of 200 mg of caffeine on vigilance, compared with a placebo, in young and middle-aged light caffeine consumers. Caffeine did not increase subjective alertness in light consumers but enhanced psychomotor performance similarly in both age groups. Furthermore, caffeine affected waking EEG spectral power in specific frequencies bands in the middle-aged group only. In conclusion, these results suggest that caffeine enhance vigilance when basal level of alertness is either high or low. Furthermore, light consumers show effects of caffeine on subjective vigilance but not on objective measures. In spite of an increase of alertness in both age groups, some modifications found in the waking EEG of middle-aged subjects suggest a differential effect of caffeine depending on age. It is possible to hypothesize that changes in the adenosinergic system occur during aging and these changes could explain our results.

G protein-coupled receptors (GPCRs) are heptahelical, transmembrane proteins that mediate a plethora of physiological functions by binding ligands and releasing G proteins that interact with downstream effectors. GPCRs signal as monomers, complexes of the same receptor subtype (homomers), or complexes of different receptor subtypes (heteromers). Recently, heteromeric GPCR complexes have become attractive targets for drug development since they exhibit distinct signaling and cell-specific localization from their homomeric counterparts. Yet, the effect of heteromerization on the pharmacology of many GPCR homomers remains unknown. Therefore, we have undertaken the task to examine the effect of heteromerization on Gs signaling through the adenosine 2A receptor (A2AR) and Gi signaling through the dopamine type 2 receptor (D2R) since the A2AR-D2R heteromer is an emerging therapeutic target for Parkinson’s disease (PD). We examined the effect of heteromerization on A2AR and D2R homomeric signaling using electrophysiology and the Xenopus laevis oocyte heterologous expression system. G protein-coupled inwardly rectifying potassium channels (GIRKs) were used as reporters for Gi signaling because activation leads to direct Gbeta-gamma (Gβγ)-mediated stimulation of the GIRK current. We also coupled GIRK channels to Gs signaling by overexpressing Gαs and signaling throughGαsβγ. Our electrophysiological assay is innovative because it allows us to optimize the conditions of heteromerization and directly observe GPCR signaling at the G protein level. Our data demonstrate that heteromer formation alone decreases dopamine-elicited Gi signaling through the D2R and CGS-21680-elicited Gs signaling through the A2AR. Furthermore, this reciprocal antagonism was predominately due to changes in efficacy versus potency. We also examined crosstalk observing that applying agonists or antagonists to the adjacent receptor further modulate this inhibition with the combination of agonists and antagonists relieving inhibition. Mutating the A2AR-D2R heteromer interface abrogated all of the aforementioned ligand-induced effects on G protein signaling through the A2AR-D2R heteromer. We are currently aiming to validate our results from the oocyte experiments with an in vivo model. Our data further elucidate the effect of various ligands on G protein signaling through the A2AR- D2R heteromer, which may facilitate future studies that examine A2AR-D2R heteromer signaling.

L'étude des populations de lymphocytes T CD4+ effecteurs (Teff) chez l'Homme présente un intérêt croissant dans les enjeux actuels que constitue l'élaboration de nouvelles immunothérapies. Ces travaux détaillent la caractérisation et la régulation d'une population de Teff exprimant l'ecto-nucléotidase CD73 ayant pour fonction de dégrader l'AMP extracellulaire en adénosine (Ado) immunosuppresseur. Cette population, enrichie en lymphocytes T helper de type Th1.17, est très polyfonctionelle et pro-inflammatoire. Les Teff CD73+ expriment peu de points de contrôles immunitaires inhibiteurs mais sont régulés par leur production autocrine d'Ado qui limite leurs fonctions effectrices et leurs capacités prolifératives. Les Teff CD73+ expriment par ailleurs fortement le transporteur ABC multidrug-resistance 1 (MDR1), responsable de l'exclusion de nombreuses drogues du cytoplasme des cellules. L'étude de cette population dans différents contextes pathologiques a permis de détailler le fonctionnement de cette population. J'ai pu mettre en évidence que l'expression de CD73 est en effet dynamique. Elle est notamment diminuée dans des pathologies arthritiques auto-immunitaires (la polyarthrite rhumatoïde et le rhumatisme psoriasique) dans lesquelles les Th17 et les Th1.17 sont fortement activés. La diminution d'expression de CD73 sur ces cellules constitue la levée d'un frein qui leur permet de contribuer pleinement à l'inflammation chronique caractérisant ces pathologies. Les Teff CD73+, présents dans les tumeurs solides humaines de sein et d'ovaire, pourraient en revanche présenter un avantage sélectif en contexte tumoral de par leur expression de MDR1 leur permettant de résister aux traitements de chimiothérapie. Ces traitements substrats de MDR1, combinés à des thérapies inhibant la fonction enzymatique de CD73, pourrait permettre la restauration d'une réponse immunitaire anti-tumorale efficace médiée par cette population pro-inflammatoire / Requirement for CD4+ effector T lymphocytes (Teff) comprehensive study in human is increasing since it can contribute to the emergence of new immunotherapy strategies. This work brings up important information concerning the characterization and regulation of a Teff population expressing the CD73 ecto-nucleotidase, which is able to degrade extracellular AMP into immunosuppressive adenosine (Ado). This population, highly polyfunctional and pro-inflammatory, is enriched in Th1.17 cells. CD73+ Teff express low levels of inhibitory immune checkpoints but are negatively regulated by the autocrine Ado production that limits their pro-inflammatory function and proliferative capacities. In addition, CD73+ Teff express high levels of the ABC transporter multi-drug resistance 1 (MDR1), responsible for the exclusion of cells’ cytoplasm of many drugs. The study of this population in different pathological contexts enabled to decipher its functions. I could evidence that CD73 expression is dynamic. CD73 is notably decreased in autoimmune arthritic pathologies (rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) in which Th1.17 and Th17 are highly activated. CD73 decreased expression by these cells is a mechanism that alleviates self-inhibition by autocrine Ado production and enables them to fully contribute to chronic inflammation characterizing these pathologies. In tumor context, CD73+ Teff present in breast and ovarian tumors could on the contrary bear a selective advantage due to their high MDR1 expression enabling them to resist MDR1 substrates-based chemotherapy treatments. These chemotherapy treatments combined to therapies blocking CD73 enzymatic function could allow the restauration of an efficient anti-tumor immune response

O uso indiscriminado de recursos ergogênicos como os esteróides anabolizantes vêm se tornando um problema crescente em diversos segmentos da população, além do meio atlético, tendo como finalidade a obtenção de melhor desempenho físico ou simplesmente melhor aparência física, porém muitas vezes sem a preocupação com os riscos dos efeitos colaterais promovidos por esta prática. No presente trabalho estudamos os efeitos da associação do uso de doses suprafisiológicas de esteróides anabolizantes e do treinamento físico aeróbio de natação sobre o fluxo sangüíneo coronário de ratos normotensos, verificando a participação da adenosina como um dos possíveis mecanismos de regulação deste fluxo, além de alterações estruturais cardíacas que poderiam influenciar na perfusão sangüínea cardíaca. Ao observarmos somente o efeito do treinamento físico, verificamos que o mesmo foi eficaz em promover adaptações benéficas ao sistema cardiovascular, como a presença de hipertrofia cardíaca fisiológica e melhora no fluxo sangüíneo coronário em repouso, provavelmente mediado por uma maior formação de adenosina circulante e cardíaca. O uso de esteróides anabolizantes associado ao treinamento físico atenuou os efeitos benéficos promovidos pelo treinamento, observando-se a presença de hipertrofia cardíaca acompanhada por redução de débito cardíaco e fluxo sangüíneo coronário, mediado por menor produção de adenosina circulante, além de prejuízo na resposta vasodilatadora à acetilcolina, demonstrando uma provável disfunção endotelial e redução na densidade capilar cardíaca, caracterizando desta forma, um quadro patológico / The abusive use of ergogenic resources as the anabolic steroid became an increasing problem in several segments of the population, beyond the athletical way, searching for better performance or physical appearance, without being worried about the risks of the collateral effects promoted by this practice. In the present work we studied the effects of the use of supraphysiological doses of anabolic steroids associated with aerobic swimming training on the coronary blood flow of normotensive rats, investigating the participation of adenosine as one of the possible mechanisms of blood flow regulation, besides the cardiac structural alterations that could influence the coronary blood perfusion. The effect of the physical training was efficient to promote beneficial adaptations of the cardiovascular system, as the presence of physiological cardiac hypertrophy and improves the coronary blood flow at rest, probably mediated by a higher circulating and cardiac adenosine production. The use of anabolic steroids associated with the swimming training attenuated the beneficial effect promoted by training, being observed the presence of cardiac hypertrophy, followed by reduction of cardiac output and coronary blood flow, mediated by lower circulating adenosine production, besides the impairment of the vasodilator response to the acetylcholine, demonstrating a probable endothelial dysfunction and reduction of the cardiac capillary density, characterizing in this way, a pathological state

A transmissão sináptica é essencial para o funcionamento do sistema nervoso. A neuromodulação permite regular esse processo de forma precisa. Um desses mecanismos modulatórios é a regulação da liberação de neurotransmissores. A adenosina é um importante modulador da transmissão sináptica. Além disso, a ativação do subtipo A2a dos receptores para adenosina está envolvida com a facilitação da liberação de neurotransmissores no sistema nervoso central. O presente trabalho teve como objetivo avaliar os efeitos modulatórios da ativação do receptor A2a de adenosina sobre a liberação de neurotransmissores e sua via de sinalização intracelular em modelo in vitro. Além disso, a tese contempla a construção histórica dos conceitos abordados no trabalho permitindo uma visão clara de sua evolução. Esse projeto foi o pioneiro no Brasil a utilizar o sensor biossintético fluorescente de liberação de vesículas sinápticas (supereclipse sinapto-pHluorina), o qual foi gentilmente cedido pelo professor Gero Miensenboeck do Sloan-Kettering Institute for Cancer Research. Nossos resultados demonstraram que o tratamento com o agonista do receptor A A2a de adenosina aumentou a fluorescência do supereclipse sinapto-pHluorina, assim como os níveis de glutamato e noradrenalina. Além disso, foi demonstrado que o inibidor da proteína cinase dependente de AMPc aboliu o aumento nos níveis do glutamato e noradrenalina, tal como a fosforilação da proteína sináptica sinapsina I evocado pelo agonista do receptor A2a de adenosina. Desta forma, nossos dados sugerem que a ativação do receptor A2a de adenosina em cultura de células do bulbo de ratos Wistar modula a liberação de neurotransmissores e a fosforilação da sinapsina I, assim como a proteína cinase dependente do AMPc pode ser o modus operandi desse fenômeno modulatório / Synaptic transmission is a sine qua non process for nervous system physiology. Such precise process is accomplished in part due to modulation of neurotransmitter release. Adenosine is a putative synaptic transmission modulator. Moreover, adenosine A2a receptor facilitates neurotransmitter release in the Central Nervous System. The present study focuses on the modulation of neurotransmission by adenosine A2a receptor and its intracellular signaling pathway in in vitro model. Here, we provided evidence that adenosine A2a receptor agonist increases an optical biosynthetic sensor of synaptic vesicle release (supereclipct synapto-pHluorin), as well as glutamate and noradrenaline. Furthermore, it was demonstrated that cAMP-dependent protein kinase inhibitor abolished glutamate and norepinephrin increase, as well as synapsin I phosphorylation evoked by adenosine A2a receptor agonist. Therefore, our data suggest that adenosine A2a receptor activation modulates neurotransmitter release and synapsin I phosphorylation in cultured cells from medulla oblongata of Wistar rats, as well as cAMP-dependent protein kinase might be the modus operandi of this modulatory phenomenon

CopA, a thermophilic membrane ATPase from Archaeoglobus fulgidus, drives the outward movement of Cu+ across cellular membranes. CopA contains at least two metal binding domains, a regulatory N-terminal Metal Binding Domain (N-MBD) and an occlusion/coordinating metal binding site in the 6th, 7th and 8th transmembrane segments. Previous studies showed that the presence of millimolar concentration of Cys is essential for CopA activity. The high affinity of CopA for metal in the presence of millimolar concentration of Cys suggests a multifaceted interaction of the enzyme with Cys. To elucidate the role of Cys, we studied its effect on the partial reactions of the catalytic cycle of CopA. We observed that 2-50 mM Cys accelerates enzyme turnover with little effect on the Cu+ affinity of CopA. Cys accelerates enzyme phosphorylation, but has no effect on the dephosphorylation rates. Thus, Cys increases steady state phosphoenzyme levels. Besides, Cys has no significant effect on E1¡ÃƒÂªE2 equilibrium. Similar results were observed in truncated CopA lacking the N-MBD suggesting that enzyme activation by Cys is independent of the regulatory metal binding sites. These results and the kinetic analysis of activation curves suggest that while Cu+ is delivered to the transport site as a Cu-Cys complex, Cys in the mM range stimulates the ATPase acting as a non-essential activator.